References
- Haas O. A., Gadner H. Pathogenesis, biology and management of myelodysplastic syndromes in children. Sem. Hematol. 1996; 33(3)225–235
- Hess J. L., Zutter M. M., Castleberry R. P., Emanuel P. D. Juvenile chronic myelogenous leukemia. Am. J. Clin. Pathol. 1996; 105: 238–248
- Papayannopoulou T., Nakamoto B., Anagnou N. P., et al. Expression of embryonic globins by erythroid cells in juvenile chronic myelocytic leukemia. Blood 1991; 77(12)2569–2576
- Niemeyer C. M., Arico M., Biondi A., et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood 1997; 89(10)3534–3543
- Aric Ú M., Biondi A., Pui C. ‐H. Juvenile myelomonocytic leukemia. Blood 1997; 90(2)479–488
- Estrov Z., Grunberger T., Chan H. S. L., Freedman M. H. Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. Blood 1986; 67(5)1382–1387
- Preudhomme C., Wattel E., Lai J. L., et al. Good predictive value of combined cytogenetic and molecular follow‐up in chronic myelogenous leukemia after non T‐cell depleted allogeneic bone marrow transplantation: a report on 38 consecutive cases. Leuk. Lymphoma 1995; 18(34)265–271
- Sires U. I., Mallory S. B., Hess J. L., et al. Cutaneous presentation of juvenile chronic myelogenous leukemia: a diagnostic and therapeutic dilemma. Pediatr. Dermatol. 1995; 12(4)364–368
- Lutz P., Zix‐Kieffer I., Souillet G., et al. Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG). Bone Marrow Transplant. 1996; 18: 1111–1116
- Rassam S. M. B., Katz E., Chessells J. M., Morgan G. Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graftversus‐leukemia effect?. Bone Marrow Transplant. 1993; 11: 247–250
- Antin J. H. Graft‐versus‐leukemia: no longer an epiphenomenon. Blood 1993; 82(8)2273–2277
- Salam A., Waer M. Graft‐versus‐host reactivity and graft‐versusleukemia effect in murine allogeneic bone marrow chimeras conditioned with total body irradiation or total lymphoid irradiation. Transplantation 1996; 61(5)826–830
- Sykes M., Pearson D. A., Szot G. L. IL‐2‐induced GVHD protection is not inhibited by cyclosporine and is maximal when IL‐2 is given over a 25 h period beginning on the day following bone marrow transplantation. Bone Marrow Transplant. 1995; 15(3)395–399
- Imamura M., Hashino S., Tanaka J. Graft‐ver‐sus‐Leukemia Effect and 1st Clinical Implications. Lenk. Lymphoma 1996; 23: 477–492
- Salutari P., Sica S., Micciulli G., et al. Extramedul‐lary relapse after allogeneic bone marrow transplantation plus buffy‐coat in two high risk patients. Haematologica 1996; 81(2)182–185